We tested the hypothesis that
clonidine-evoked
hypotension is dependent on central adenosinergic pathways. Five groups of male, conscious, aortic baroreceptor-denervated (ABD) rats received
clonidine (10 microg/kg i.v.) 30 min after i.v. 1) saline, 2)
theophylline (10 mg/kg), or 3) 8-(p-sulfophenyl)
theophylline (8-SPT) (2.5 mg/kg) or 1 h after i.p. 4)
dipyridamole (5 mg/kg) or 5) an equal volume of
sesame oil. Blockade of central (
theophylline) but not peripheral (8-SPT)
adenosine receptors abolished
clonidine hypotension. In contrast,
dipyridamole substantially enhanced the bradycardic response to
clonidine. In additional groups, intracisternal (i.c.)
dipyridamole (150 microg) and 8-SPT (10 microg) enhanced and abolished, respectively,
clonidine (0.6 microg i.c.)-evoked
hypotension. Because
clonidine is a mixed I1/alpha2 agonist, we also investigated whether
adenosine signaling is linked to the I1 or the alpha2A receptor by administering the selective I1 (
rilmenidine, 25 microg) or alpha2A [
alpha-methylnorepinephrine (alpha-MNE), 4 microg] agonist 30 min after central
adenosine receptor blockade (8-SPT; 10 microg i.c.) or artificial cerebrospinal fluid. The hypotensive response elicited by
rilmenidine or alpha-MNE was abolished in 8-SPT-pretreated rats. To delineate the role of the
adenosine A2A receptor in
clonidine-evoked
hypotension, i.c.
clonidine (0.6 microg) was administered 30 min after central
adenosine receptor A2A blockade [5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-epsilon]-1,2,4-triazolo[1,5-c]-
pyrimidine (
SCH58261); 150 microg i.c.]. The latter virtually abolished the hypotensive and bradycardic responses elicited by
clonidine. In conclusion, central
adenosine A2A signaling plays a key role in
clonidine-evoked
hypotension in conscious aortic barodenervated rats.